SEC Form 4Coverage since Jun 1, 2026
$IONS insider trading
Over the last 12 months, Ionis Pharmaceuticals insiders reported 1 buy totaling $1.1M and 13 sales totaling $19.7M across SEC Form 4 filings. 93% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $1.1M 1 event
- Sold · 12m
- $19.7M 13 events
- Events · 12m
- 14 Form 4 filings, grouped
- Insiders · 12m
- 11 distinct reporters
- 10b5-1 share
- 93% pre-arranged plans
Side
Price · $IONS · 12Mvia TradingView
Top insiders · 12m
BERTHELSEN SPENCER R—2× · $1.2M
BENNETT C FRANKEVP, Chief Scientific Officer2× · $1.7M
Kordasiewicz Holly B.EVP, Chief Development Officer2× · $4.5M
Hayden Michael R—1× · $1.1M
O'NEIL PATRICK R.EVP CLO & General Counsel1× · $246K
All insider trades
14 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | Hayden Michael RD | ▲ Buy | 20,000 | $52.94 | $1.1M | +500% | 2 tranches · indirect |
| Jul 7, 2026 | BENNETT C FRANKEVP, Chief Scientific Officer · O | ▼ Sale | 15,000 | $85.46 | $1.3M | -100% | plan · indirect |
| Jul 7, 2026 | BENNETT C FRANKEVP, Chief Scientific Officer · O | ▼ Sale | 5,536 | $83.58 | $463K | -6.9% | plan |
| Jul 7, 2026 | Diaz Allene M.D | ▼ Sale | 10,111 | $85.42 | $864K | -72.6% | plan |
| Jul 7, 2026 | Kordasiewicz Holly B.EVP, Chief Development Officer · O | ▼ Sale | 362 | $84.3 | $31K | -1.6% | plan |
| Jul 1, 2026 | KLEIN JOSEPH IIID | ▼ Sale | 11,518 | $79.04 | $910K | -51.1% | plan · 2 tranches |
| Jun 26, 2026 | Baroldi JosephEVP, Chief Business Officer · O | ▼ Sale | 5,635 | $80.16 | $452K | -54.7% | plan · indirect |
| Jun 26, 2026 | O'NEIL PATRICK R.EVP CLO & General Counsel · O | ▼ Sale | 3,069 | $80 | $246K | -4.8% | plan |
| Jun 26, 2026 | Schneider EugeneEVP, Chf Clinical Develop Ofcr · O | ▼ Sale | 26,000 | $81.05 | $2.1M | -25.2% | plan |
| Jun 26, 2026 | Monia Brett PChief Executive Officer · O·D | ▼ Sale | 85,637 | $79.7 | $6.8M | -25.9% | plan · 3 tranches |
| Jun 25, 2026 | Swayze EricEVP Research · O | ▼ Sale | 10,602 | $79.18 | $839K | -32.8% | plan |
| Jun 15, 2026 | BERTHELSEN SPENCER RD | ▼ Sale | 8,000 | $73.49 | $588K | -4.9% | plan |
| Jun 12, 2026 | Kordasiewicz Holly B.EVP, Chief Development Officer · O | ▼ Sale | 60,846 | $73.41 | $4.5M | -73% | plan · 2 tranches |
| Jun 1, 2026 | BERTHELSEN SPENCER RD | ▼ Sale | 8,000 | $75.67 | $605K | -4.9% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $IONS feed.